GLMD (Galmed Pharmaceuticals) EPS without NRI: $-2.02 (TTM As of Dec. 2025)


GLMD Galmed Pharmaceuticals Ltd GLMD
27 GF Score
Price $0.57
! 2 Warning Signs
View Full Analysis

What is Galmed Pharmaceuticals EPS without NRI?

Galmed Pharmaceuticals GLMD -11.95% 27 EPS without NRI is $-2.02 as of Dec. 2025. GuruFocus rates GLMD with a GF Score™ of 27/100. The stock has 2 warning signs investors should review. Among 1,170 Biotechnology companies, Galmed Pharmaceuticals ranks better than 94.62% on this metric.

Galmed Pharmaceuticals's earnings per share without non-recurring items for the three months ended in Dec. 2025 was $-0.57. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was $-2.02.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Galmed Pharmaceuticals's EPS without NRI or its related term are showing as below:

GLMD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -34.5   Med: 10.7   Max: 75.7
Current: 75.7

GLMD's 3-Year EPS without NRI Growth Rate is ranked better than
94.62% of 1170 companies
in the Biotechnology industry
Industry Median: 16.75 vs GLMD: 75.70

Galmed Pharmaceuticals's EPS (Diluted) for the three months ended in Dec. 2025 was $-0.92. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-2.50.

Galmed Pharmaceuticals's EPS (Basic) for the three months ended in Dec. 2025 was $-0.92. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was $-2.50.


Galmed Pharmaceuticals  (NAS:GLMD) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Galmed Pharmaceuticals EPS without NRI Related Terms


Galmed Pharmaceuticals EPS without NRI Historical Data

* Premium members only.

The historical data trend for Galmed Pharmaceuticals's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galmed Pharmaceuticals EPS without NRI Chart

Galmed Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -236.83 -124.29 -30.94 -6.88 -1.78

Galmed Pharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.26 -0.62 -0.50 -0.33 -0.57

GLMD vs FBLG, SXTP, CELZ: EPS without NRI Comparison

For the Biotechnology subindustry, Galmed Pharmaceuticals's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galmed Pharmaceuticals PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galmed Pharmaceuticals's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Galmed Pharmaceuticals's PE Ratio without NRI falls into.


GLMD
27GF Score
Galmed Pharmaceuticals Ltd GLMD
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Galmed Pharmaceuticals EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of $-2.02 mean?
Galmed Pharmaceuticals (GLMD) has a EPS without NRI of $-2.02 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Galmed Pharmaceuticals and its competitors. According to the industry distribution chart, Galmed Pharmaceuticals ranks #63 out of 1170 companies in the Biotechnology industry, placing it in the top 5.4%.
Is Galmed Pharmaceuticals' EPS without NRI too high?
Galmed Pharmaceuticals' current EPS without NRI is $-2.02. Based on the distribution chart, Galmed Pharmaceuticals ranks #63 out of 1170 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Galmed Pharmaceuticals has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Galmed Pharmaceuticals' EPS without NRI compare to FBLG and SXTP?
According to the Biotechnology industry distribution chart, Galmed Pharmaceuticals ranks #63 out of 1170 companies for EPS without NRI. This places Galmed Pharmaceuticals in the top 5% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 16.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.75, based on 1,170 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Galmed Pharmaceuticals and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Galmed Pharmaceuticals's current EPS without NRI is $-2.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galmed Pharmaceuticals stock overvalued right now?
Galmed Pharmaceuticals (GLMD) has a current EPS without NRI of $-2.02. The current EPS without NRI is $-2.02. Galmed Pharmaceuticals' overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Galmed Pharmaceuticals (GLMD), the current EPS without NRI is $-2.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Galmed Pharmaceuticals Business Description

Address c/o Meitar Law Offices, 16 Abba Hillel Road, Ramat Gan, ISR, 5250608
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. The company focuses on the development of Aramchol for combination therapy for GI oncological indications. The company is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline targeting GI, cardiometabolic indications and other product candidates.
27GF Score

Get the complete analysis for GLMD

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.57
Price